Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
IRVINE, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC:CLSC) (BULLETIN BOARD: CLSC) , a pharmaceutical development company specializing in anti-allergy medications, announced today...
FDA's Office of Nonprescription Products Will Now Handle Marketing Approval Process for Anti-Allergy Drug PreHistin(TM) IRVINE, Calif., Jan. 19 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC:CLSC...
Thomas Stankovich, Former Vice President and Chief Financial Officer of MP Biomedicals, Ribapharm and ICN / Valeant Pharmaceuticals Joins Cobalis Corp. as Chief Financial Officer IRVINE, Calif...
European Patent Office Allows New Patent for PreHistin(TM) -- 'Cyanocobalamin Treatment in Allergic Disease' IRVINE, Calif., Nov. 2 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC:CLSC) (BULLETIN...
Safe, Non-Drowsy PreHistin(TM) Achieves Clinical and Statistical Significance (p= 0.0028) Versus Placebo; Study Demonstrates Dramatic Reduction in Allergy Symptoms IRVINE, Calif., Oct. 27...
IRVINE, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC:CLSC) (BULLETIN BOARD: CLSC) , a pharmaceutical biotech company specializing in the development of anti-allergy medications...
Cobalis Corp. Phase III Trial for PreHistin(TM) Shows Positive Results for Pre-Seasonal Treatment to Mitigate Allergy Symptoms in Humans IRVINE, Calif., July 20 /PRNewswire-FirstCall/ -- Cobalis...
Nasdaq Notifies Cobalis That It Will Remove 'V' From Its Stock Symbol -- an Update on Mandatory Share Certificate Exchange IRVINE, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC...
Cobalis Changes Its Trading Symbol From "CBSC" to "CLSC" - Update on Mandatory Share Certificate Exchange IRVINE, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC:CBSC) (BULLETIN...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
